intercell

  1. T

    Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investiga

    Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic...
Back
Top